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Abstract
Background Although young age is considered a risk factor
for adverse events related top r o c e d u r a ls e d a t i o na n d
analgesia (PSA), data in very young children (<2 years of
age) are lacking.
Aims The main objective of our study is to describe PSA in
children <2 years of age in an inner city tertiary care pediatric
emergency department (PED).
Methods We conducted a retrospective chart review from
January 2005 to June 2007 of children <2 years of age who
received PSA in our PED. We collected demographic var-
iables, indication for and medications used for PSA, adverse
events (AE) related to PSA, and interventions performed to
treat them.
Results Of the children who received PSA, 14.5% (180/
1,235) were <2 years of age of whom 173 were included for
the analysis; 73% (126/173) of the study subjects were be-
tween 1 and 2 years of age, 54.3% (94/173) were male, and
96.5% (167/173) belonged to American Society of Anes-
thesiologists class 1. Incision and drainage (45.0%, 78/173)
and laceration repair (32.4%, 56/173) were the two most
common indications for PSA. Ketamine and midazolam was
the most common combination medication used for PSA
(62.4%, 108/173). Sedation was deemed ineffective in 5.8%
(10/173)ofthechildren.Therewereonlytwofailedsedations;
5.8% (10/173) of the children experienced AE with most
being minor [oxygen desaturations 1.7% (3/173), emesis
2.3% (4/173), and others 1.2% (2/173)]. One child experi-
enced serious AE in the form of apnea and bradycardia
requiring intubation.
Conclusions Our data suggest that children under 2 years
of age can be sedated effectively without increased risk of




Providing relief from pain and anxiety associated with
diagnostic and therapeutic procedures has become an ethical
imperative in children as well as a measured quality indicator
from the family’s perspective. This, along with a tremendous
increase in the number of procedures performed on children
outside the operating room, has led to non-anesthesiologists,
particularly emergency physicians, taking a key role in the
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children. It has been estimated that roughly a quarter million
children will receive PSA in the emergency departments
(EDs) annually and that children under 2 years of age
constitute roughly 20–30% of those [1, 2]. It has been shown
that pain in infants and toddlers is poorly recognized and
documented [3, 4], predisposing them to receive less
analgesia when compared with older children [5]. Common-
ly used medications for PSA such as ketamine are relatively
contraindicated in very young children (<6 months of age)
because of an association with increased risk of airway
complications [6]. Inadequate sedation and analgesia predis-
poses to procedural failure, parental anxiety and dissatisfac-
tion, and poor quality of care. The anatomic differences in
the airway like smaller airway diameter, longer and floppy
epiglottis, and the physiologic differences in drug metabo-
lism between younger and older children could predispose
younger children to a higher risk for adverse events related
to sedation. Studies have shown contrasting results regarding
association of age and adverse events related to PSA. While
some studies have found children less than 2 years of age to
be at an increased risk for adverse events related to PSA [7,
8], other studies have found no association between age and
adverse events related to PSA [9, 10]. To our knowledge,
there have been no studies that have focused exclusively on
PSA in children less than 2 years of age. The main objective
of our study is to describe PSA in children less than 2 years
of age in the ED of a tertiary care children’s hospital. Addi-
tionally, we will describe the indications for PSA, medi-
cations used, efficacy of sedation, and adverse events related
to sedation in this group of children.
Methods
Weconducteda retrospectivechartreviewofmedicalrecords,
including sedation records of all children less than 2 years of
age who underwent PSA in our ED over a period of 2.5 years
from January 2005 to June 2007. Our ED is a level 1 trauma
center of a tertiary care, freestanding children’sh o s p i t a lw i t h
greater than 90,000 visits a year. Study subjects were
identified using their date of birth and the Current Procedural
Terminology (CPT) code used for procedural sedation in the
ED (99141). All patients who undergo PSA in the ED have a
standardized nursing sheet that records all events during the
PSA procedure till discharge from the ED. Children who
received only pain medication, or analgesia, and those who
underwentsedationintheimagingdepartmentbythe sedation
team were excluded from the study.
We used a standardized data abstraction sheet to collect
patient demographic variables, past medical history including
American Society of Anesthesiologists (ASA) class, indica-
tions and medications used for PSA, and service of the phy-
sician (for example ED attending or consultant services like
pediatric surgery, hand surgery, etc.) performing the proce-
dure. We collected data on effectiveness of sedation, adverse
events related to sedation, the interventions performed to
overcome the adverse events, and ED disposition. For the
purposes of the study, the following were considered as ad-
verse events: oxygen desaturations less than 93% for greater
than 15 s, apnea, aspiration, laryngospasm, bradycardia, hypo-
tension, paradoxical reaction, emesis, and any other that were
reported by the sedating physician as an adverse event.
Sedation was deemed as inadequate if the procedure was
completedbutwithsignificantpatientdistressasdocumentedin
the nursing notes or movement during the procedure. Failed
sedation was defined as the inability to complete the procedure
in the ED. All data were abstracted and entered by the principal
investigator to maintain consistency. All data were double en-
tered for accuracy. This study was approved by the Institutional
Review Board.
Statistical analysis was conducted using the commercial
software SAS v. 9.1 (SAS Institute Inc., Cary, NC, USA).
Descriptive statistics (frequency, mean, standard deviation,
and 95% confidence interval) was used to summarize the
characteristics of the study sample. The chi-square test and
Student’s t-test were used to compare the differences in the
number of medications used and medication dosages
between patients with adequate sedation versus those with
inadequate sedation.
Results
Over the study period of 2.5 years, there were a total of
225,750 patient visits to the ED. A total of 1,235 PSAs were
performed, of which 14.6% (180/1235) were performed in
children under the age of 2 years. Of these, seven children
were excluded from review and analysis. We were unable to
obtain medical records for 5 children, 1 child received only
analgesia, and 1 child was sedated by the sedation service for
diagnostic imaging, leaving 173 patients eligible for analysis.
The majority of patients (73%, 126/173) receiving PSAwere
between 1 and 2 years of age (Fig. 1), 54.3% (94/173) were
male, and 96.5% (167/173) belongedto ASA class 1. Incision
and drainage (45.0%, 78/173) and laceration repair (32.4%,
56/173) were the two most common indications for PSA in
this age group (Fig. 2). The procedure was performed by the
consultant services (non-ED attending) in 77% (133/173) of
the patients. The average duration of the procedure requiring
PSA was 17.3±13.9 minu The majority of the children
received a combination of two medications for PSA (80.4%,
139/173). Ketamine/midazolam (62.4%, 108/173) was the
most common combination medication used for PSA
followed by morphine/midazolam (16.1%, 28/173) reflective
of institutional practice.
174 Int J Emerg Med (2008) 1:173–177Sedation was “inadequate” in 5.8% (10/173) of the
patients. There was no difference in patient age, number of
medicationsused,andmeanweight-baseddosageofketamine
and morphine used between those with adequate versus
inadequate sedation. The mean dosage of midazolam used
was slightly higher in those children with inadequate sedation
(Table 1). The planned procedure could not be completed
successfully in only two children. Both of these were pro-
cedure failures and not sedation failures. The first case was a
2-month-old male child who was adequately sedated with
ketamine and midazolam but failed reduction of an incarce-
rated inguinal hernia. This child also subsequently developed
apnea related to PSA. The second patient was a 6-month-old
female child who had to be taken to the operating room after
failure of reduction of hernia under sedation with morphine
(0.2 mg/kg) and midazolam (0.1 mg/kg).
Of the patients, 5.8% (10/173) experienced adverse events
related to PSA (Table 2). Most (9/10) of these adverse events
were minor in nature and included transient oxygen desatu-
rations (1.7%,3/174),emesis(2.3%,4/173),andothers(1.2%,
2/173), which included snoring and development of transient
stridor. All these adverse events resolved with minimal
interventions including repositioning the airway, oral suction-
ing, and oxygen supplementation.
One study subject experienced a serious adverse event, in
the formofapnea and bradycardia, which required intubation.
This was a 2-month-old male child with a history of recent
upper respiratory tract infection and an overnight admission
for bronchiolitis 1 week prior to the visit that required PSA.
He required PSA for an incarcerated right-sided inguinal
hernia. He received two doses of ketamine (total of 2 mg/kg)
and two doses of midazolam (total of 0.2 mg/kg). Approxi-
mately 30 min after the failed reduction he developed
persistent hypoxia and bradycardia which did not respond to
supplemental oxygen or airway maneuvers and subsequently
became apneic requiring endotracheal intubation. He was
extubated 2 days later and had an uncomplicated recovery.
Discussion
Our study results suggest that PSA is safe and can be per-
formedsuccessfullyinchildrenlessthan2years ofage.These
results are consistent with previous studies which have de-
monstratedthe proficiencyofemergencymedicinephysicians
to deliver PSA effectively in children of all age groups [9, 11,
12]. There were only two failed sedations in our study. Both
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Fracture Reduction Lumbar Puncture
Hernia Reduction Diagnostic Imaging
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0-3months 3.1-6 months 
6.1-12months 12.1-24 months
Fig. 1 Age distribution of study population
Int J Emerg Med (2008) 1:173–177 175(<6 months of age), were procedure failures, and occurred
during hernia reduction. This may underscore the need for
reduction in the operating room rather than in the emergency
department for the youngest children.
Interestingly, abscess incision and drainage was the most
common indication for PSA in our study population. Other
studies have reported that fracture reduction and laceration
repair are more common indications [9, 12], and the differ-
ence in indications could be reflective of our study popu-
lation or could reflect the reported increase in the ED visits
for skin and soft tissue infections secondary to the emer-
gence of community-acquired methicillin-resistant Staphylo-
coccus aureus [13].
Our study demonstrates a low adverse event rate related to
PSA in children less than 2 years of age. More importantly,
most of the observed adverse events were minor and transient
requiringonlyminimalintervention.Malviyaetal.[8]i nt h e i r
study of adverse events related to sedation of children by
non-anesthesiologists concluded that young age (less than
1 year of age) was a predictor of adverse events. However,
the majority of patients in their study underwent sedation for
diagnostic imaging and three fourths of the children were
sedated with chloral hydrate, a drug that is not commonly
used for PSA in the emergency department. Although Peña
et al. [9] in their prospective study of adverse events related
to PSA in a pediatric emergency department reported that
one third of the observed total adverse events occurred in
children up to 2 years of age, in their final analysis they were
unable to find a difference between those who experienced
adverse events and those who did not, with respect to age.
We did have one serious adverse event related to PSA in
ourstudy.Thispatient servestohighlightthatsafetyofPSAis
dependent on patient characteristics and that adequate
monitoring is essential during and after the procedure until
the patient is ready for discharge. It also emphasizes the need
for physicians providing PSA to have necessary skills to
rescue the patient from a deeper level of sedation than that
intended for the procedure and provide appropriate cardio-
pulmonary support if needed [14].
Limitations
The biggest limitation to our study was its retrospective
nature, which could have limited the amount of information
Table 2 Adverse events related to procedural sedation and analgesia
Age (months) Sex Procedure Medication dose (mg/kg) Adverse event Treatment
2 M Hernia reduction Midazolam (2) Apnea, bradycardia Intubation
Ketamine (0.2)
15 M Laceration repair Midazolam (0.17) Oxygen desaturation Oxygen supplementation
Ketamine (1.29)
10 M Incision & drainage Midazolam (0.09) Oxygen desaturation Oxygen supplementation
Ketamine (0.95)
22 M Laceration repair Midazolam (0.13) Oxygen desaturation Oxygen supplementation
Ketamine (1.52)
15 F Laceration repair Midazolam (0.13) Stridor Airway repositioning,
racemic epinephrine Ketamine (1.02)
9 M Incision & drainage Ketamine (0.98) Snoring Airway repositioning
22 M Laceration repair Midazolam (0.13) Vomiting Suction
Ketamine (1.52)
4 M Incision & drainage Midazolam (0.14) Vomiting Suction
Morphine (0.21)
23 M Laceration repair Midazolam (0.09) Vomiting Suction
Ketamine (0.89)
23 F Laceration repair Midazolam (0.09) Vomiting Suction
Ketamine (0.94)
Table 1 Comparison of children with adequate versus inadequate
sedation
Variable Adequate sedation Inadequate
sedation
p value
n Percentage n Percentage
Age
0–1 years 43 93.5 3 6.5 0.820
1–2 years 118 94.4 7 5.6
No. of medication(s) received
One 22 13.8 2 20.0 0.582
Two or more 138 86.2 8 80.0
Medication dosage n mg/kg (SD) n mg/kg (SD)
Morphine 29 0.140 (0.078) 2 0.120 (0.071) 0.731
Versed 133 0.099 (0.057) 8 0.144 (0.045) 0.032
Ketamine 128 1.211 (0.568) 8 1.326 (0.348) 0.571
176 Int J Emerg Med (2008) 1:173–177that was available. We reviewed not only the medical
records of the study children but also the sedation records.
The sedation records were audited every 3 months during
the study period to ensure completeness of data recorded in
these records. There could have also been variation amongst
physicians and nurses as to what constitutes an adverse event
related to PSA leading to overreporting or underreporting of
the adverse event rate. But this under/overreporting is less
likely because of a standardized monitoring plan for all
patients undergoing PSA in the ED. We also did not study
the adverse events after discharge from the emergency
department. This study was undertaken at a tertiary care
pediatric emergency department and the findings may not be
applicable to other settings with differentlevels of training of
the sedation providers and different monitoring practices.
Our center also uses ketamine predominantly for PSA. The
adverse event rate and profile may be different in other
centers which use other medications for PSA.
Conclusion
OurstudyshowsthatPSAcanbeadministeredeffectivelyand
safely with few adverse events to children less than 2 years of
age in a pediatric emergency department.
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